ACADIA Pharmaceuticals Net Income
| ACAD Stock | USD 24.59 1.54 5.89% |
As of the 3rd of February, ACADIA Pharmaceuticals owns the market risk adjusted performance of 0.2075, and Coefficient Of Variation of 848.42. ACADIA Pharmaceuticals technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices. Please confirm ACADIA Pharmaceuticals mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and information ratio to decide if ACADIA Pharmaceuticals is priced adequately, providing market reflects its prevailing price of 24.59 per share. Given that ACADIA Pharmaceuticals has jensen alpha of 0.1758, we suggest you to validate ACADIA Pharmaceuticals's latest market performance to make sure the company can sustain itself at some future date.
ACADIA Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 3.3037 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 203.8 M | 214 M | |
| Net Loss | -194.4 M | -204.1 M | |
| Net Income From Continuing Ops | 260.4 M | 273.4 M | |
| Net Income Per Share | 1.23 | 1.29 | |
| Net Income Per E B T | 0.79 | 0.81 |
ACADIA | Net Income | Build AI portfolio with ACADIA Stock |
Analyzing ACADIA Pharmaceuticals's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing ACADIA Pharmaceuticals's current valuation and future prospects.
Latest ACADIA Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of ACADIA Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ACADIA Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of ACADIA Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ACADIA Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ACADIA Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 226.45 M | 10 Years Trend |
|
Net Income |
| Timeline |
ACADIA Net Income Regression Statistics
| Arithmetic Mean | (86,610,759) | |
| Geometric Mean | 112,857,591 | |
| Coefficient Of Variation | (199.96) | |
| Mean Deviation | 139,305,549 | |
| Median | (92,475,000) | |
| Standard Deviation | 173,191,065 | |
| Sample Variance | 29995.1T | |
| Range | 515.9M | |
| R-Value | 0.31 | |
| Mean Square Error | 29007.1T | |
| R-Squared | 0.09 | |
| Significance | 0.23 | |
| Slope | 10,480,659 | |
| Total Sum of Squares | 479922.3T |
ACADIA Net Income History
Other Fundumenentals of ACADIA Pharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
ACADIA Pharmaceuticals Net Income component correlations
ACADIA Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ACADIA Pharmaceuticals is extremely important. It helps to project a fair market value of ACADIA Stock properly, considering its historical fundamentals such as Net Income. Since ACADIA Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ACADIA Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ACADIA Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could ACADIA diversify its offerings? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ACADIA Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.128 | Earnings Share 1.55 | Revenue Per Share | Quarterly Revenue Growth 0.113 | Return On Assets |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that ACADIA Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ACADIA Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, ACADIA Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
ACADIA Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ACADIA Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ACADIA Pharmaceuticals.
| 11/05/2025 |
| 02/03/2026 |
If you would invest 0.00 in ACADIA Pharmaceuticals on November 5, 2025 and sell it all today you would earn a total of 0.00 from holding ACADIA Pharmaceuticals or generate 0.0% return on investment in ACADIA Pharmaceuticals over 90 days. ACADIA Pharmaceuticals is related to or competes with ADMA Biologics, Praxis Precision, Ligand Pharmaceuticals, Belite Bio, Soleno Therapeutics, Mirum Pharmaceuticals, and Crinetics Pharmaceuticals. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small mole... More
ACADIA Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ACADIA Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ACADIA Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.65 | |||
| Information Ratio | 0.0903 | |||
| Maximum Drawdown | 9.79 | |||
| Value At Risk | (2.46) | |||
| Potential Upside | 3.35 |
ACADIA Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ACADIA Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ACADIA Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use ACADIA Pharmaceuticals historical prices to predict the future ACADIA Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0928 | |||
| Jensen Alpha | 0.1758 | |||
| Total Risk Alpha | 0.1023 | |||
| Sortino Ratio | 0.1108 | |||
| Treynor Ratio | 0.1975 |
ACADIA Pharmaceuticals February 3, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0928 | |||
| Market Risk Adjusted Performance | 0.2075 | |||
| Mean Deviation | 1.65 | |||
| Semi Deviation | 1.48 | |||
| Downside Deviation | 1.65 | |||
| Coefficient Of Variation | 848.42 | |||
| Standard Deviation | 2.03 | |||
| Variance | 4.11 | |||
| Information Ratio | 0.0903 | |||
| Jensen Alpha | 0.1758 | |||
| Total Risk Alpha | 0.1023 | |||
| Sortino Ratio | 0.1108 | |||
| Treynor Ratio | 0.1975 | |||
| Maximum Drawdown | 9.79 | |||
| Value At Risk | (2.46) | |||
| Potential Upside | 3.35 | |||
| Downside Variance | 2.73 | |||
| Semi Variance | 2.18 | |||
| Expected Short fall | (1.93) | |||
| Skewness | 0.6316 | |||
| Kurtosis | 0.3485 |
ACADIA Pharmaceuticals Backtested Returns
ACADIA Pharmaceuticals appears to be very steady, given 3 months investment horizon. ACADIA Pharmaceuticals retains Efficiency (Sharpe Ratio) of 0.14, which signifies that the company had a 0.14 % return per unit of risk over the last 3 months. We have found twenty-seven technical indicators for ACADIA Pharmaceuticals, which you can use to evaluate the volatility of the entity. Please makes use of ACADIA Pharmaceuticals' market risk adjusted performance of 0.2075, and Coefficient Of Variation of 848.42 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, ACADIA Pharmaceuticals holds a performance score of 10. The firm owns a Beta (Systematic Risk) of 1.16, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ACADIA Pharmaceuticals will likely underperform. Please check ACADIA Pharmaceuticals' information ratio, treynor ratio, and the relationship between the downside deviation and total risk alpha , to make a quick decision on whether ACADIA Pharmaceuticals' current price history will revert.
Auto-correlation | -0.67 |
Very good reverse predictability
ACADIA Pharmaceuticals has very good reverse predictability. Overlapping area represents the amount of predictability between ACADIA Pharmaceuticals time series from 5th of November 2025 to 20th of December 2025 and 20th of December 2025 to 3rd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ACADIA Pharmaceuticals price movement. The serial correlation of -0.67 indicates that around 67.0% of current ACADIA Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.67 | |
| Spearman Rank Test | -0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 0.61 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ACADIA Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ACADIA Pharmaceuticals reported net income of 226.45 M. This is 33.65% lower than that of the Biotechnology sector and 223.29% higher than that of the Health Care industry. The net income for all United States stocks is 60.34% higher than that of the company.
ACADIA Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ACADIA Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ACADIA Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ACADIA Pharmaceuticals by comparing valuation metrics of similar companies.ACADIA Pharmaceuticals is currently under evaluation in net income category among its peers.
ACADIA Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ACADIA Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ACADIA Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
ACADIA Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in ACADIA Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of ACADIA Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing ACADIA Pharmaceuticals' value.| Shares | Dimensional Fund Advisors, Inc. | 2025-06-30 | 2.4 M | Fred Alger Management, Llc | 2025-06-30 | 2.4 M | Rockefeller Capital Management L.p. | 2025-06-30 | 2.3 M | Marshall Wace Asset Management Ltd | 2025-06-30 | 2 M | D. E. Shaw & Co Lp | 2025-06-30 | 2 M | Assenagon Asset Management Sa | 2025-06-30 | 1.7 M | Citigroup Inc | 2025-06-30 | 1.7 M | Pictet Asset Manangement Sa | 2025-06-30 | 1.6 M | American Century Companies Inc | 2025-06-30 | 1.6 M | Baker Bros Advisors Lp | 2025-06-30 | 42.9 M | Blackrock Inc | 2025-06-30 | 20.7 M |
ACADIA Fundamentals
| Return On Equity | 0.35 | ||||
| Return On Asset | 0.0511 | ||||
| Profit Margin | 0.25 % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 3.46 B | ||||
| Shares Outstanding | 169.18 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 99.46 % | ||||
| Number Of Shares Shorted | 8.37 M | ||||
| Price To Earning | (13.77) X | ||||
| Price To Book | 4.63 X | ||||
| Price To Sales | 4.22 X | ||||
| Revenue | 957.8 M | ||||
| Gross Profit | 617.77 M | ||||
| EBITDA | 100.16 M | ||||
| Net Income | 226.45 M | ||||
| Cash And Equivalents | 436.35 M | ||||
| Cash Per Share | 2.70 X | ||||
| Total Debt | 51.99 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 4.53 X | ||||
| Book Value Per Share | 5.42 X | ||||
| Cash Flow From Operations | 157.72 M | ||||
| Short Ratio | 6.59 X | ||||
| Earnings Per Share | 1.55 X | ||||
| Price To Earnings To Growth | (0.42) X | ||||
| Target Price | 31.37 | ||||
| Number Of Employees | 653 | ||||
| Beta | 0.66 | ||||
| Market Capitalization | 4.42 B | ||||
| Total Asset | 1.19 B | ||||
| Retained Earnings | (2.2 B) | ||||
| Working Capital | 543.45 M | ||||
| Current Asset | 603.49 M | ||||
| Current Liabilities | 39.15 M | ||||
| Net Asset | 1.19 B |
About ACADIA Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ACADIA Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ACADIA Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ACADIA Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:Check out For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could ACADIA diversify its offerings? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ACADIA Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.128 | Earnings Share 1.55 | Revenue Per Share | Quarterly Revenue Growth 0.113 | Return On Assets |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that ACADIA Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ACADIA Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, ACADIA Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.